At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, ...
Kardigan(TM), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results